title: Does diabetes affect [(18)F]FDG standardised uptake values in lung cancer?
abstract: The correlation of hyperglycaemia with decreased 2-[(18)F]fluoro-2-deoxy- D-glucose (FDG) uptake by tumours in positron emission tomography (PET) imaging has been clearly established. The available data are mainly based on non-diabetic (non-DM) patients exposed to acute hyperglycaemia after glucose infusion, and little is known about the effect of diabetes mellitus (DM) on FDG uptake by tumours. In this retrospective study we performed a comparison of the tumour uptake in 40 DM patients with the tumour uptake in 145 non-DM patients, all with primary lung malignancies. Peak standardised uptake values (SUVs) without glucose correction were calculated for the lung lesions. Mean (+/-standard deviation) blood glucose concentrations were 6.58+/-2.46 mmol/l in the DM patients and 4.39+/-0.89 mmol/l in the non-DM patients. There was no significant difference between tumour SUVs in DM patients (79 lesions), 5.86+/-3.97, and those in non-DM patients (234 lesions), 6.47+/-4.61. There was no significant difference between tumour SUVs in DM patients with blood glucose <7 mmol/l ( n=28, 64 lesions), 5.91+/-3.98, and those in DM patients with blood glucose >7 mmol/l ( n=12, 15 lesions), 5.68+/-4.09. There was also no significant difference between myocardial SUVs in the DM patients ( n=40), 3.28+/-2.75, and in a similar group of non-DM patients ( n=42), 3.30+/-2.24. We conclude that FDG uptake in lung tumours is not significantly influenced by blood glucose levels in diabetic patients whose blood glucose levels are reasonably well controlled.
authors.affiliation: Department of Nuclear Medicine, Rebecca Sieff Government Hospital, Safed, Israel.
authors.forename: Miguel
authors.initials: M
authors.lastname: Gorenberg
authors.forename: William A
authors.initials: WA
authors.lastname: Hallett
authors.forename: Michael J
authors.initials: MJ
authors.lastname: O'Doherty
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000032:analysis; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood / Q000378:metabolism*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics* / Q000592:standards; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000150:complications* / Q000000981:diagnostic imaging / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011786:Quality Control; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000592:standards; D012015:Reference Standards; D012016:Reference Values; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D013223:Statistics as Topic; D014018:Tissue Distribution
chemical_list: D001786:Blood Glucose; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18